Tampilkan postingan dengan label Trump Administration. Tampilkan semua postingan
Tampilkan postingan dengan label Trump Administration. Tampilkan semua postingan

Senin, 21 Agustus 2017

4 policy ideas to improve health care BEFORE single payer

4 policy ideas to improve health care BEFORE single payer


Today's Managing Health Care Costs Number is 4

I get angry when politicians and candidates pledge to implement "single payer health care," but are mum about what they would do right now to improve the health care system and enable a future transition to single payer when the political system is ripe for such a move.  

Here are four suggestions for efforts that "single payer" advocates should promote right now. All are consistent with continuing the employer sponsored health insurance system that we now have. That's important because
employers pay about 20% of total costs ($720 billion a year), and it will take some time to replace that contribution!  All of these ideas could garner some degree of bipartisan support, and all could be implemented at (relatively) low cost and with dedicated revenue streams.   All would also be opposed by someone - since there are a lot of parties within the medical care industry who are doing quite well under the current expensive, fragmented, and low quality system. 

All of these ideas would be better promoted federally than by state, as the federal government is better able to spend dollars during economic downturns, and since the need for these solutions is often highest in those states least likely to act progressively themselves. Progressive states can lead the way, though, and these incremental approaches are more likely to be financially sustainable than full-blown immediate state implementation of single payer, as shown by unsuccessful single payer efforts in Vermont and California.

  1. Provide national (or state) coverage for high cost insurance beneficiaries.  

    Remove high cost members from the fragmented insurance system when they hit a set point (such as $100,000) -and provide insurance coverage for these members through a pool funded by a levy on all insurance plans. This can be modeled on the reinsurance arrangement that was in the Affordable Care Act, and would need to include levies on self-insured insurance plans.  This would be easier to do through federal legislation and regulation; states are poorly positioned to intervene in ERISA-regulated self-insured plans. Nationalizing coverage for the highest cost beneficiaries would lower the desire for insurers or employers to seek to "dump" high risk members/employees, and it would mean that those with such severe illness would no longer face financial ruin. It could be administered by CMS, which already administers such a program for those with end stage renal disease.  

Katherine Swarz of the Harvard TH Chan School of Public Health has written extensively about this for two decades.

This won't be easy. Reinsurers, providers who care for the super-sick, and pharmaceutical companies could feel threatened by this. High cost individuals will need to be disenrolled when they are no longer high cost. But this will make the current market stronger by eliminating some gaming incentives, and could serve as a way to gradually increase the portion of the medical budget that is financed through a single payer.
  1. Provide access to the Federal Employee Health Benefits program in counties without at least 2 Affordable Care Act plans

    Competition is good!  The FEHB already insures 8 million beneficiaries in all 50 states.  The FEHB is managed competition - and some single payer advocates will object that this undermines the single payer cause.   Au contraire!  FEHB is a single payer with multiple health plans arranging the care - and there are many developed countries that have a single payer which "subs out" the care arrangement to dozens (or hundreds) of independent health plans.  The exchange market simply isn't robust in rural areas and areas with provider concentration - let's be sure that rural Americans have access to choice just like those of us who live in the cities.

    Health plans might object - and FEHB administrators won't be happy with a new mandate that probably comes without adequate resources.  But this is more business for the health plans that participate in FEHB - and a great model for eventual single payer.

     
  2. Provide universal coverage for maternity care

    Having a baby is expensive - and the quality of maternity care in the US is horrendous and we are the only developed country with
    increasing maternal mortality.  Young families have relatively lower income than a generation ago, and are often burdened by student loans and huge housing expenses.   Do we really want them to decide to put off having kids because of the expense?  Universal coverage of maternity care is the ultimate pro-life policy, and could help address our declining birth rate and diminish our economic need for immigration. 

    Obstetricians and hospitals might be unhappy - Medicaid currently pays for over 49% of births- and pays lower rates (by about 50%).  Does anyone want pregnant women to not have coverage for their prenatal care and deliveries?

     
  3. Provide universal coverage for kids

    Kids are cheap!  There are a few expensive neonatal ICU babies (there will be fewer if we have universal maternity coverage), and a few kids get leukemia or have horrible diseases.  But overall, the costs of adding universal pediatric coverage are tiny.   Kids are our future.   Kids who have access to medical coverage have better academic outcomes, are less likely to land in jail, and will pay more in taxes over their lifetimes.  Childhood vaccinations are one of the two medical services that genuinely save money beyond their costs. (The other is birth control, and the
    Trump Administration is effectively reversing the ACA coverage mandate).   Also- for those who think that laziness or sloth is responsible for poverty, kids didn't do anything "wrong" to land on the wrong side of the wealth divide in our country.

Pediatricians are more likely than other physicians to accept Medicaid, and the loss to hospitals will be small as kids aren't hospitalized that much.  Fees for kids could be set somewhere between Medicaid and private insurance rates so that we don't produce a devastating shortage of pediatricians in the future through underfunding now.

There you have it.  Four things that can be done now to make health care better and advance the cause of single payer at some point in the future.  So next time a politician says "I will get together a committee to  discuss next steps," don’t accept that answer!


Rabu, 02 Agustus 2017

Payment reform speed bump

Payment reform speed bump




Today's Managing Health Care Cost Number is 92

MACRA, the  Medicare Access and CHIP Reauthorization Act, passed Congress in 2015 with huge bipartisan majorities (397-37 in the House and 92-8 in the Senate), and many feel that this means that payment reform in the US has unstoppable momentum.

MACRA was passed when it seemed likely the next President would want to continue the Obama legacy in health care, and when there was finally a Congressional Budget Office cost estimate that made it feasible to repeal the Sustainable Growth Rate regulations, which had  threatened massive cuts in professional Medicare payments each year.   Republicans like Tom Price, now the HHS Secretary, voted "aye" to take giant Medicare physician fee cuts off the table.  But their commitment to payment reform was never clear.

MACRA includes substantial future fee cuts to physicians who don’t adopt electronic medical records and meet certain quality goals, and allows physicians who are part of alternative payment methods like accountable care organizations to escape from these rules.   The provider community has made a huge investment in migrating into "risk" arrangements for Medicare and non-Medicare patients, and to build the infrastructure to be able to manage the health of populations, as opposed to just issuing fee for service bills.

An article in StatNews yesterday shows that Tom Price is working feverishly to undermine MACRA - and free physicians to continue to practice in the old "fee for service" way for the foreseeable future.

Doctors — many of whom have been vocally opposed to the efforts to repeal Obamacare — are over the moon about the steady drumbeat of regulatory rollbacks… “We’re not used to having wins, and all of a sudden we’re getting these rules where a lot of what we asked to have happen is happening,” said one physician industry official, speaking on condition of anonymity to speak candidly.

Tom Price and the Center for Medicare and Medicaid Services have retrospectively diminished the "stick" pushing physicians toward using  EMRs or putting in safety processes ; physicians who failed to meet 2016 requirements will not be penalized as scheduled in 2018.  He has also exempted more physicians from MACRA requirements.

CMS has also delayed expansion  of the Comprehensive Care for Joint Replacement, and has expressed opposition to the Obama Administration's preferred approach of implementing this program in randomly chosen communities - which would have made facilitated rigorous studies of its impact.  CMS is also delaying the Cardiac Rehabilitation Incentive Payment Model -and the Trump Administration has pushed for defunding of the Centers for Medicare and Medicaid Innovation, which has coordinated many payment reform initiatives.

Many still believe payment reform is inevitable. But changing payment methodologies is hard- and most likely to succeed if Medicare leads the way.   92 senators is not a big enough majority to drive payment reform with an administration not fully committed to the effort. 

Kamis, 22 Juni 2017

Lowering drug prices by raising drug prices.

Today's Managing Health Care Costs Number is 1/6


Kaiser Health News and the New York Times have reported on the four page Trump executive order to decrease drug prices.    He's going for irony -- he will decrease drug prices by raising them.

The recommendation comes from Trump's Drug Pricing and Innovation Workgroup, which is chock full of pharma industry executives.  As Kaiser Health News reports:

To solve the crisis of high drug prices, the group discussed strengthening the monopoly rights of pharmaceuticals overseas, ending discounts for low-income hospitals and accelerating drug approvals by the Food and Drug Administration. 

So - the administration thinks that if pharma companies are able to earn more dollars in India or Brazil they will lower their prices in the US?    That's simply not how pricing works!  The pharmaceutical companies have been plenty profitable overall and that has not led to any relief of steady price inflation.  Drug companies charge what the market will pay - and allowing them higher profits in one arena doesn't simply lower prices somewhere else. New oncology and specialty drugs routinely cost over $100,000 a year, and price increases on existing medications continue to outpace inflation.

The Administration would also decrease 340b discounts to hospitals and providers who serve low income communities.   Exactly how that would help drug prices?   It would increase pharmaceutical industry profitability allowing the drug companies to lower their prices overall.   Does anyone really believe that?

There's more.   The executive order could allow pharmaceutical companies to provide marketing material to insurers and pharmacy benefit managers before FDA approval, and "use less rigorous clinical trial standards to speed drug approvals."  I can see how this could decrease value (encouraging the use of new expensive drugs with little or no benefit beyond older established drugs).  But I can't see how this will decrease cost!

The FDA released a blog post promising action to prevent brand name legal tactics that delay introduction of generic medications.  That is one element of the Trump plan that could lead to some price relief.   However, the problem we face is the cost of brand name drugs.  We should push to get faster approval for generics, and we should allow importation of generics from other developed countries when we face shortages in the US. 

But we need action to decrease the price of new medications.   There are potential answers out there:
  • Medicare could negotiate prices (prohibited by the Medicare Part D enabling legislation).
  • The FDA could consider cost in drug approval (prohibited by current rules). 
  • The National Institutes of Health could "march in" and retake patents for drugs which are priced too high
  • We could implement an excise tax on excessive prices.  We could enable payments for expensive effective medications over the period of benefit rather than "up front."  

Here are a set of recommendations from Consumer Reports

But the Trump Administration drug plan is the answer to the pharmaceutical industry's wish list. It will raise overall drug costs abroad through actions to protect patents, and it will raise overall drug costs here by cracking down on 340b discounts. 

Senin, 24 April 2017

Health care crowds out other government spending


Today’s Managing Health Care Costs Number is $937 billion



The National Academy of Medicine published a commentary about the future of health care policy priorities in JAMA two weeks ago.  They exhort us to pay for value, empower people, activate communities and connect care – and to measure what matters, modernize skills, accelerate real-world evidence, and advance science.  All of these priorities make sense –and are especially important in light of Saturday’s March(es) for Science.

What caught my eye more than these important priorities, though, was statistics on how health care is essentially gobbling up government spending.   In 1974, one in $20 spent by the government was on health care.   In 2015 it was $1 in $4!

That’s good for employment, and it’s good for innovation in health care.  We live longer and better lives in 2017 than we did in 1974.  

But there are consequences.  The Environmental Protection Agency budget was $7.9 billion in 2000 – and was $8.1 billion in 2016.  But the paltry increase masks a huge decline in the inflation adjusted budget.  The inflation adjusted budget in 2000 would have been $10.9 billion – so the 2016 budget was a 25% decline.  The EPA employed over 18,000 in 1998; this had declined to under 15,400 in 2016 – a 15% drop.    All of this is before the almost 1/3 cut in the EPA budget proposed by the Trump Administration. 

A healthy environment leads to lower rates of disease and healthier Americans – and is usually more cost-effective (or even cost-saving) than investments in medical care.  For instance, the Clean Air Act has a cost:benefit ratio of beween 4:1 and 10:1.  We need to control medical care costs to leave room in the federal budget for other important initiatives.








Senin, 06 Maret 2017

 Doubts on payment reform could stall health care transformation

Doubts on payment reform could stall health care transformation


Payment reform on its own will not cure our high medical costs.  We need to make fundamental changes in the way we deliver care - and that won't happen just because some care is no longer paid for via "fee for service."  

Changes that we need include:
  • Advancing "disruptive innovations," that lower costs dramatically even if they lack some elements of traditional care. (This includes midwifery delivery in birth centers for low risk pregnancy, and lightweight ultrasounds that can be used at the point of care)
  • Increased coordination among providers
  • Better "hot spotting" to identify the highest risk patients and prevent hospital admissions
  • Evidence based use of imaging
  • Providers who are sensitive to resource cost of what they order

Right now, health care providers are doing well overall - and changing the underlying business is a threat to that success.   Payment reform provides the necessary threat to push integrated delivery networks and other provider organizations to seriously consider making changes that could lower revenue. 

So while payment reform alone won't lead to higher value care, lack of the viable threat of payment reform could halt progress on health care delivery redesign.   Why should a CFO agree to an expensive program to halt high margin but preventable hospital admissions?

I co-teach a provider payment course in a graduate degree program for mid-career physician executives at the Harvard TH Chan School of Public Health. Watching these talented physicians and learning about the efforts they are making to transform health care in their organizations has made me guardedly optimistic about the chances that the "accountable care" movement could substantially improve health care value.

This weekend, the buzz was around a comment by one of the professors that "MACRA is dead."   MACRA, the Medicare Access and CHIP Reauthorization Act, which eliminated the physician "sustainable growth rate (SGR)" regulations which would have cut Medicare professional reimbursement by more than a quarter, defined specific Medicare penalties for providers who were not effectively using electronic medical records, and allowed physicians participating in alternative payment models to avoid these penalties.

MACRA was passed by a bipartisan majority in 2015 (54-45 in the Senate and 392-37 in the House).  So some have felt that the payment reform in MACRA is "safe."   I'm afraid I disagree.

MACRA had the support of many conservative Republicans who voted for this in part because it eliminated the hated SGR. Many, including now-HHS Secretary Tom Price, have argued that the Obama Administration rulemaking around the bill would create undue demands on physicians.  Price argued that payment reform should be voluntary.    But voluntary bundled payments don't create the burning platform necessary to drive change in health care delivery.

Some delivery systems that have been deeply committed to transforming themselves will push ahead with efforts to improve quality of care and lower costs.  But many systems are likely to put such efforts on the slow track, as they wait to see whether the Trump administration will do the hard work of administrative rulemaking to support payment reform.

As we discussed the prospects for payment reform, I sensed a deep sigh of disappointment among these physician executives who have devoted their professional lives to redesigning health care.